Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 79.2%

Neg 0% Neu 0% Pos 79.2%

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.